Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F2PO
|
|||
| Former ID |
DAP000025
|
|||
| Drug Name |
Pindolol
|
|||
| Synonyms |
Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Tocris Bioscience
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H20N2O2
|
|||
| Canonical SMILES |
CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
|
|||
| InChI |
1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
|
|||
| InChIKey |
JZQKKSLKJUAGIC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 13523-86-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9286447, 11113889, 14798566, 14798567, 17404912, 17405585, 24278026, 26732601, 26752052, 44871985, 46530676, 48169371, 48256917, 48318405, 48393931, 50104702, 50104703, 50661418, 53777455, 53778133, 57408548, 85787587, 90341477, 91721940, 92303745, 103340603, 103966357, 109890703, 121361223, 124749642, 124799687, 128350665, 135650828, 135697987, 137149274, 162022836, 162247517, 163127011, 163564303, 175270310, 179149848, 196369461, 226396988, 241182092, 241375191
|
|||
| ChEBI ID |
CHEBI:8214
|
|||
| ADReCS Drug ID | BADD_D01776 | |||
| SuperDrug ATC ID |
C07AA03
|
|||
| SuperDrug CAS ID |
cas=013523869
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 91). | |||
| REF 2 | Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997 Nov 1;157(9):1245-54. | |||
| REF 3 | Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.